Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination product** containing three components: - **Mavacamten**, a small molecule that acts as a selective, allosteric, and reversible inhibitor of cardiac myosin, reducing hypercontractility of the heart muscle and used primarily in the management of symptomatic obstructive hypertrophic cardiomyopathy (HCM)[1][2][3][4][5]. - **Activated charcoal**, a form of carbon processed to have small, low-volume pores that increase surface area for adsorption; in medicine, it is used to treat some types of poisoning by binding to substances in the gastrointestinal tract and preventing their absorption. - **Sorbitol**, a sugar alcohol often used as a laxative or as a component in medicinal formulations; when combined with activated charcoal, it can hasten gastrointestinal transit and elimination of toxins. There is no evidence of this specific triple combination being an approved pharmaceutical product. If formulated, it could theoretically be used to facilitate the gastrointestinal elimination of mavacamten in overdose scenarios (by adsorption and hastening elimination), though this is speculative.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mavacamten + activated charcoal + sorbitol.